Haematologica (Jan 2017)
Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis
- Tobias Herold,
- Stephanie Schneider,
- Klaus H. Metzeler,
- Martin Neumann,
- Luise Hartmann,
- Kathryn G. Roberts,
- Nikola P. Konstandin,
- Philipp A. Greif,
- Kathrin Bräundl,
- Bianka Ksienzyk,
- Natalia Huk,
- Irene Schneider,
- Evelyn Zellmeier,
- Vindi Jurinovic,
- Ulrich Mansmann,
- Wolfgang Hiddemann,
- Charles G. Mullighan,
- Stefan K. Bohlander,
- Karsten Spiekermann,
- Dieter Hoelzer,
- Monika Brüggemann,
- Claudia D. Baldus,
- Martin Dreyling,
- Nicola Gökbuget
Affiliations
- Tobias Herold
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
- Stephanie Schneider
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
- Klaus H. Metzeler
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
- Martin Neumann
- German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Department of Hematology, Oncology and Tumor Immunology, Charité Universitätsmedizin Berlin, Germany
- Luise Hartmann
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
- Kathryn G. Roberts
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, USA
- Nikola P. Konstandin
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
- Philipp A. Greif
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
- Kathrin Bräundl
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
- Bianka Ksienzyk
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
- Natalia Huk
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
- Irene Schneider
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
- Evelyn Zellmeier
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
- Vindi Jurinovic
- Institute for Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität (LMU), München, Germany
- Ulrich Mansmann
- Institute for Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität (LMU), München, Germany
- Wolfgang Hiddemann
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
- Charles G. Mullighan
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, USA
- Stefan K. Bohlander
- Department of Molecular Medicine and Pathology, The University of Auckland, New Zealand
- Karsten Spiekermann
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany;German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany
- Dieter Hoelzer
- Department of Medicine II, Goethe University Hospital, Frankfurt, Germany
- Monika Brüggemann
- Department of Hematology, University Hospital Schleswig-Holstein Campus Kiel, Germany
- Claudia D. Baldus
- German Cancer Consortium (DKTK), Heidelberg, Germany;German Cancer Research Center (DKFZ), Heidelberg, Germany;Department of Hematology, Oncology and Tumor Immunology, Charité Universitätsmedizin Berlin, Germany
- Martin Dreyling
- Department of Internal Medicine 3, University Hospital Grosshadern, Ludwig-Maximilians-Universität (LMU), München, Germany
- Nicola Gökbuget
- Department of Medicine II, Goethe University Hospital, Frankfurt, Germany
- DOI
- https://doi.org/10.3324/haematol.2015.136366
- Journal volume & issue
-
Vol. 102,
no. 1
Abstract
Philadelphia-like B-cell precursor acute lymphoblastic leukemia (Ph-like ALL) is characterized by distinct genetic alterations and inferior prognosis in children and younger adults. The purpose of this study was a genetic and clinical characterization of Ph-like ALL in adults. Twenty-six (13%) of 207 adult patients (median age: 42 years) with B-cell precursor ALL (BCP-ALL) were classified as having Ph-like ALL using gene expression profiling. The frequency of Ph-like ALL was 27% among 95 BCP-ALL patients negative for BCR-ABL1 and KMT2A-rearrangements. IGH-CRLF2 rearrangements (6/16; P=0.002) and mutations in JAK2 (7/16; P
